Efficacy and safety of the muscarinic receptor agonist KarXT(xanomeline-trospium)in schizo-phrenia(EMERGENT-2)in the USA:Results from a randomised,double-blind,placebo-controlled,flexible-dose phase 3 trial
Efficacy and safety of the muscarinic receptor agonist KarXT(xanomeline-trospium)in schizo-phrenia(EMERGENT-2)in the USA:Results from a randomised,double-blind,placebo-controlled,flexible-dose phase 3 trial
国家科技期刊平台
NSTL
维普
万方数据